Dr. Jason Luke Describes Results from the Phase III COMBI-d Trial

Dr. Jason Luke Talks About Advances in how Melanoma is DiagnosedПодробнее

Phase 3 COMBI-d trial of dabrafenib plus trametinib in metastaticПодробнее

Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With MelanomaПодробнее

Jason Luke, MD: Second-Line TherapyПодробнее

Dr. Luke on Combining an IDO Inhibitor With Nivolumab in Advanced CancersПодробнее

Dr. Jason Luke Discusses the Giants of Cancer Care ProgramПодробнее

Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ MelanomaПодробнее

Dr. Jason Luke Discusses Nivolumab and Pembrolizumab in MelanomaПодробнее

COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanomaПодробнее

Dr. Luke on Treatment Options in Metastatic MelanomaПодробнее

Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy ResponseПодробнее

Dr. Jason Luke on the Importance of Discussing Value-Based CareПодробнее

ECC 2015: New survival data from Combi-v trial of combination of two targeted therapies in melanomaПодробнее

Jason Luke, MD: The Impact of BRAF/MEK Inhibitors in MelanomaПодробнее

Dr. Robert on Next Steps Following the Phase III COMBI-v Study in MelanomaПодробнее

Dr. Robert on the Phase III COMBI-v Study in BRAF-Mutant MelanomaПодробнее

Exploring Intratumoral Immunotherapy in Melanoma and Other MalignanciesПодробнее

Jason J. Luke, MD, FACP, on how data from ESMO 2019 may impact the treatment of melanomaПодробнее

COMBI-d: a phase III study on the combination of dabrafenib and trametinib in patients with melanomaПодробнее